Ovid Therapeutics logo
September 9, 2016

Ovid Therapeutics Receives Orphan Drug Designation

Ovid Therapeutics, a privately held biopharmaceutical company based in New York City, announced that the U.S. Food and Drug Administration has granted orphan drug designation to OV101 for the treatment of patients with Angelman syndrome. See the press release. 

Read more